The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Minireview: Inflammation: An Instigator of More Aggressive Estrogen Receptor (ER) Positive Breast Cancers
Open accessAbstract
Approximately 75% of breast tumors express the estrogen receptor (ER), and women with these tumors will receive endocrine therapy. Unfortunately, up to 50% of these patients will fail ER-targeted therapies due to either de novo or acquired resistance. ER-positive tumors can be classified based on gene expression profiles into Luminal A- and Luminal B-intrinsic subtypes, with distinctly different responses to endocrine therapy and overall patient outcome. However, the underlying biology causing this tumor heterogeneity has yet to become clear. This review will explore the role of inflammation as a risk factor in breast cancer as well as a player in the development of more aggressive, therapy-resistant ER-positive breast cancers. First, breast cancer risk factors, such as obesity and mammary gland involution after pregnancy, which can foster an inflammatory microenvironment within the breast, will be described. Second, inflammatory components of the tumor microenvironment, including tumor-associated macrophages and proinflammatory cytokines, which can act on nearby breast cancer cells and modulate tumor phenotype, will be explored. Finally, activation of the nuclear factor κB (NF-κB) pathway and its cross talk with ER in the regulation of key genes in the promotion of more aggressive breast cancers will be reviewed. From these multiple lines of evidence, we propose that inflammation may promote more aggressive ER-positive tumors and that combination therapy targeting both inflammation and estrogen production or actions could benefit a significant portion of women whose ER-positive breast tumors fail to respond to endocrine therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adipokines in inflammation and metabolic disease
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011) · Nature Reviews Immunology · doi:10.1038/nri2921 · Cited by 4,625
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 1×
“The NF- B pathway A key downstream mediator of proinflammatory cytokines is the NF- B family of transcription factors, which is known to play a critical role in the development and progression of a variety of tumors (28, 94).”
BackgroundThe two NF-κB activation pathways and their role in innate and adaptive immunity
Bonizzi, G., & Karin, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.008 · Cited by 2,535
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
Reeves, G. K., Pirie, K., Beral, V., Green, J., Spencer, E., & Bull, D. (2007) · BMJ · doi:10.1136/bmj.39367.495995.ae · Cited by 1,507
Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases
Park, J. Y., Pillinger, M. H., & Abramson, S. B. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.01.016 · Cited by 793
Aging and proinflammatory cytokines
Bruunsgaard, H., Pedersen, M., & Pedersen, B. K. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200105000-00001 · Cited by 690
Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer
Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., & Hall, B. M. (2007) · The FASEB Journal · doi:10.1096/fj.07-8832com · Cited by 222
Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2
Wang, X., Belguise, K., Kersual, N., Kirsch, K. H., Mineva, N. D., Galtier, F., Chalbos, D., & Sonenshein, G. E. (2007) · Nature Cell Biology · doi:10.1038/ncb1559 · Cited by 209
Cited by
Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
Feitelson, M. A., Arzumanyan, A., Kulathinal, R. J., Blain, S. W., Holcombe, R. F., Mahajna, J., Marino, M., Martinez-Chantar, M. L., Nawroth, R., Sanchez-Garcia, I., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.006 · Cited by 778
Cruceriu, D., Baldasici, O., Balacescu, O., & Berindan-Neagoe, I. (2020) · Cellular Oncology · doi:10.1007/s13402-019-00489-1 · Cited by 524
The Role of Cytokines in Breast Cancer Development and Progression
Esquivel-Velázquez, M., Ostoa-Saloma, P., Palacios-Arreola, M. I., Nava-Castro, K. E., Castro, J. I., & Morales-Montor, J. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0026 · Cited by 490
Omega-3 fatty acids for breast cancer prevention and survivorship
Fabian, C. J., Kimler, B. F., & Hursting, S. D. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0571-6 · Cited by 311
A comprehensive analysis of breast cancer microbiota and host gene expression
Thompson, K. J., Ingle, J. N., Tang, X., Chia, N., Jeraldo, P. R., Walther-Antonio, M. R., Kandimalla, K. K., Johnson, S., Yao, J. Z., Harrington, S. C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188873 · Cited by 183
Metadata
- Authors
- Baumgarten, S. C., & Frasor, J.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2012-03-01
- Volume
- 26
- Issue
- 3
- Pages
- 360-371
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2074143255
- Cited by
- 172
- References
- 9
- FWCI
- 9.92
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Minireview: Inflammation: An Instigator of More Aggressive Estrogen Receptor (ER) Positive Breast Cancers. https://app.cochat.ai/papers/10.1210/me.2011-1302
- The paper
- Baumgarten, S. C., & Frasor, J. (2012). Minireview: Inflammation: An Instigator of More Aggressive Estrogen Receptor (ER) Positive Breast Cancers. Molecular Endocrinology. https://doi.org/10.1210/me.2011-1302
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.